Litcius/Paper detail

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)

Jianhua Shi, Ying Cheng, Qiming Wang, Kai Li, Lin Wu, Baohui Han, Gongyan Chen, Jianxing He, Jie Wang, Haifeng Qin, Xiaoling Li

2022Frontiers of Medicine18 citationsDOI

Topics & Concepts

PlaceboMedicineInternal medicineClinical endpointLung cancerAdverse effectOncologySubgroup analysisChemotherapyGastroenterologyRandomized controlled trialConfidence intervalPathologyAlternative medicineLung Cancer Research StudiesNeuroendocrine Tumor Research AdvancesCancer therapeutics and mechanisms
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202) | Litcius